Nomura Analyst Sees Fast Growth At Biomarin Pharmaceutical - Yahoo Finance

Ian Somaiya boosted his target on the company by 6 percent to $123, maintaining a Buy rating and calling it his "top pick" among mid-cap drug makers. BIoMarin, with 2013 sales of $548.5 million, has five approved products and multiple clinical and pre-clinical product candidates. "We expect a data rich next 12-to-15 months," Somaiya said. Somaiya raised his peak sales estimate for the company's drisapersen treatment for a form of muscular dystrophy to an annual rate of $1.25 billion, with marketing approval expected in 2019. BioMarin expects to pick up drisaperson in part of its acquisition of Prosensa Holding N.V. For the original version including any supplementary images or video, visit

NYSE Market Notifies Aoxing Pharmaceutical Company, Inc. Of Extension of Time for Compliance - Yahoo Finance

The Exchange also granted the Company an extension until December 31, 2014 to regain compliance with Section 1003(a)(iv). On January 13, 2015, the Exchange notified the Company that the period during which it will be permitted to regain compliance with Section 1003(a)(iv) has been extended to January 23, 2015. The Company will be subject to periodic review by the Exchange Staff during the extension periods. Failure to make progress consistent with the plans or to regain compliance with the listing standards by the ends of the extension periods could result in the Company being delisted from the NYSE MKT LLC. About Aoxing Pharmaceutical Company, Inc. Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. For the original version including any supplementary images or video, visit

Board approves funding for job creation at 4 Iowa companies - Yahoo News

Regal Entertainment Group, down $1.08 to $20.01 The movie theater company decided against a sale, saying the move would not be in the best interest of its shareholders. Schlumberger Ltd., up $4.70 to $81.33 The oil and gas exploration technology and services company reported better-than-expected fourth-quarter profit and cut jobs in response to falling oil prices. UBS AG, down 30 cents $16.23 The Swiss bank agreed to pay $14.4 million to settle charges it failed to disclose information about its "dark pool" trading system. Nasdaq Viacom Inc., up $1.59 to $68.07 The media and entertainment company extended the contract of its President and CEO Philippe Dauman by two years through 2018. Depomed Inc., up $2.55 to $20.20 The pharmaceutical company will pay $1.05 billion to buy the U.S. rights to Johnson & Johnson's Nucynta pain drug franchise. Tessera Technologies Inc., up $3.67 to $37.22 The technology company entered a settlement agreement with Amkor Technology Inc. and raised its recurring revenue guidance. For the original version including any supplementary images or video, visit

Johnson & Johnson Ebola groups get $117M in funding - Yahoo News

Johnson & Johnson said the Innovative Medicines Initiative will give 100 million euros ($117 million) to groups its Janssen Pharmaceutical unit is forming with research institutions and non-governmental organizations. The New Brunswick, New Jersey-based company announced earlier this month the start of an early-stage clinical trial for its Ebola vaccine. The company plans to contribute up to $200 million to speed up development of the vaccine and expand production of the medicine for larger clinical trials. Johnson & Johnson said it expects to produce 2 million regimens, which are made up of one shot that primes the immune system and a second booster shot, available this year. The company also plans to investigate ways to raise awareness and acceptance of its vaccine. The largest Ebola outbreak in history started in December 2013 in Guinea, West Africa. The World Health Organization says more than 21,000 people are believed to have been infected and almost 8,500 have died. Johnson & Johnson shares rose $1.55 to $104.04. Pharmaceuticals & Drug Trials For the original version including any supplementary images or video, visit

Precision Castparts and UBS are big market movers - Yahoo News

Innovation funding was also approved for three startups in Des Moines, Coralville and Clinton. The awards are meant to help create 96 jobs and spur statewide economic growth. Board director Debi Durham said providing both financial assistance and tax benefits to these companies aids the increase and improvement of opportunities for Iowans. Companies receiving funding include: Alter Trading Corporation, a metal recycling company in Davenport: Construction of a new facility near the company's existing plant is expected to create 13 jobs. Barilla, an Italian-based company located in Ames: Two additional production lines, raw material storage and more are planned for the existing facility, a project expected to create 23 jobs. Cambrex Charles City, Inc., a pharmaceutical manufacturer in Charles City: An estimated 32 jobs will be created as the company looks to increase manufacturing capacity with a new facility. For the original version including any supplementary images or video, visit